Breadth of cancers reviewed with VTE
| Cancer site | Total N=457 (%) | DVT/PE (N=205/252) |
|---|---|---|
| Lung | ||
| NSCLC | 39 | 8/31 |
| SCLC | 6 | 2/4 |
| Mesothelioma | 5 | 1/4 |
| Total | 50 (11%) | 11/39 |
| Upper GI | ||
| Gastro-oesophageal | 28 | 20/18 |
| Hepatobiliary | 12 | 10/2 |
| Pancreatic | 13 | 7/6 |
| Total | 53 (11.6%) | 27/26 |
| Breast | 86 (18.8%) | 51/35 |
| Gynaecological | ||
| Ovary | 27 | 9/18 |
| Endometrium | 13 | 3/10 |
| Cervix | 4 | 2/2 |
| Vulva | 5 | 2/3 |
| Total | 49 (10.7%) | 16/33 |
| Male urological | ||
| Renal | 20 | 11(5 IVC)/10 |
| Bladder | 10 | 6/4 |
| Prostate | 36 | 20/16 |
| Genital | 5 | 3/2 |
| Total | 71 (15.5%) | 39/32 |
| Brain | 8 (1.8%) | 6/2 |
| Colorectal | ||
| Caecum | 14 | 6/8 |
| Ascending/transverse/descending colon | 40 | 13/27 |
| Sigmoid/rectum/anus | 59 | 21/38 |
| Total | 113 (24.7%) | 40/73 |
| Unknown primary | 9 (2%) | 4/5 |
| Miscellaneous | 18 (3.9%) | 10/8 |
DVT, deep vein thrombosis; PE, pulmonary embolus; NSCLC, non small cell lung cancer, SCLC, small cell lung cancer; GI, gastrointestinal; IVC, inferior vena cava; VTE, venous thromboembolism.